CCT245737

CCT245737 (SRA737) is an orally active and seletive Chk1 inhibitor, with an IC50 of 1.3 nM.

Product Specifications

CAS Number

[1489389-18-5]

Product Name Alternative

SRA737

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Checkpoint Kinase (Chk)

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/CCT245737.html

Purity

99.48

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

FC(F)(F)C(C=NC(NC1=CN=C(C#N)C=N1)=C2)=C2NC[C@H]3CNCCO3

Molecular Formula

C16H16F3N7O

Molecular Weight

379.34

Precautions

H315, H319, H335

References & Citations

[1]Osborne JD, et al. Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R) -5- ((4- ((Morpholin-2-ylmethyl) amino) -5- (trifluoromethyl) pyridin-2-yl) amino) pyrazine-2-carbonitrile (CCT245737) . J Med Chem. 2016 Jun 9;59 (11) :5221-37.|[2]Walton MI, et al. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma.